Oxford PV is developing a solid state dye sensitized solar cell which is optimised to drive a paradigm shift in the aesthetics, performance and cost of Building Integrated Photovoltaic (BIPV) systems.
Major focus is on the development of novel biologics for cancer and infectious disease. For more than 27 years, Amgen scientists have applied innovative research to advance important new therapies for grievous illnesses. Amgen’s heritage lies in leading-edge molecular biology. This basic science platform permitted the development of protein therapeutics that have transformed the management of anaemia, inflammation, and cancer.
More recently, Amgen has assembled a multidisciplinary group of chemists and biologists who, together, approach the challenge of drug discovery using multiple potential therapeutic modalities. The research program that was started 27 years ago has grown spectacularly, yielding a heightened understanding of human disease, and innovative new approaches to improving human health.
Absynth Biologics is focussed on the development of vaccines and antibodies to treat bacterial infection. The company’s distinctive approach uses genomics to identify highly conserved bacterial protein targets, essential for life and capable of stimulating the immune system. Absynth’s lead programme focuses on infections caused by the bacterium Staphylococcus aureus (S. aureus) including its more difficult-to-treat drug-resistant form, methicillin-resistant S. aureus (MRSA).
Insception Lifebank offers expectant parents a professionally acknowledged quality service. Along with being the first to achieve the AABB accreditation, Insception Lifebank is the first family cord blood bank in Canada to receive the industry’s highest accreditation, FACT.
Kapplex solutions are powered by Digital Microfluidics (DMF) technology which overcome the challenges of conventional channel microfluidics. With the lack of moving parts, valves or tubes, DMF devices are capable of manipulating droplet-sized fluids on simple, low cost platforms with high flexibility and easy multiplexing.
Smart Well PlateTM High-throughput assays for precious sample analysis
Smart ScreenTM for dried blood analysis Low-cost on-chip blood sample analysis
Xagenic is a molecular diagnostics company developing a true point- of-care platform. Our aim is to enable on-demand, near patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of first consultation. This will dramatically improve patient care and reduce health care costs.
INTERFACE BIOLOGICS, INC. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices.
Our primary technology focus areas are anti-thrombogenic additives that reduce thrombosis and programmable combination drug delivery devices.
The company was founded in 2001 based on the work of Dr. Paul Santerre at the University of Toronto. The name, Interface Biologics, comes from the critical interface between the human body and medical devices at the molecular level.
BIOX Corporation is a spin off of University of Toronto specialized in renewable energy and designs, builds, owns and operates a 67 million litre per annum nameplate capacity biodiesel production facility in Hamilton, Ontario Canada. Their innovative production process is significantly faster and achieves higher yields than competing methods while utilizing the widest variety of feedstocks ranging from pure seed oils to animal fats to recovered vegetable oils with no change to our production process. Their high quality biodiesel fuel meets North American (ASTM) quality standards.
Changing the way fuels are made…
The Oxford Catalysts Group is helping to create a better fuel future through innovation in processing technology
Therapure Biopharma Inc. is an integrated contract development and manufacturing organization (CDMO) that develops and manufactures (upstream and downstream processing) therapeutic proteins as well as provides aseptic fill/finish services for both complex biologics and small molecules.
Therapure Biopharrma Inc. has been awarded the Gold Leaf Award for Emerging Company of the Year by BIOTECanada in the Health Biotech Category for 2012. Therapure has been recognized as an outstanding emerging health company for the potential of its unique biomanufacturing capabilities as well as its highly innovative drug discovery pipeline.
IXO is a biotechnology company researching and developing novel immunotherapeutics targeting the innate immune system. Focusing on the initiators of the adaptive immune response, IXO’s products address significant unmet clinical need in areas of high commercial value. Based in the UK, IXO’s products are in late-stage research and preclinical development based on IP derived from both NERC
and the University of Oxford.
Oxford Imaging Detectors is developing high performance scientific imaging detectors capable of studying structures and processes at the atomic level. Initially focussed for use in electron microscopy, the detectors were developed by the research group lead by Professor Angus Kirkland at the University’s Department of Materials. They provide significant advantages over current technology, exceeding the current state of the art in speed, contrast, efficiency and resolution.
Intelligent Ultrasound develops software that improves significantly the quality, field of view and diagnostic power of medical ultrasound scans.
The company’s application-specific products are based on a clinically proven and proprietary technology platform that is the subject of multiple peer-review publications.
Oxehealth, spun out from Oxford’s Institute of Biomedical Engineering, will allow patient’s health to be monitored using a webcam and a software application.
The software will detect a patient’s heart rate, respiratory rate and oxygen saturation even in artificial light without the need for any physical contact or additional hardware.
A spin-out from the University of Oxford, Oxford Vacmedix, will commercialise a new technology with the potential to reduce the cost of vaccine development significantly and increase the effectiveness of vaccines in providing immunity against both infectious diseases and cancer. The technology makes use of techniques that have already produced effective vaccines under laboratory conditions.
Hyperion Therapeutics’ RAVICTI(TM) (glycerol phenylbutyrate) Liquid Receives FDA Approval for Treatment of Urea Cycle Disorders
Feb. 1, 2013: Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the U.S. Food and Drug Administration (FDA) has approved RAVICTI for the treatment of Urea Cycle Disorders (UCD) in patients two years of age and older. The drug is expected to be commercially available by the end of April 2013.
Oxygen Biotherapeutics and the U.S. Army Institute of Surgical Research Sign a Cooperative Research and Development Agreement to Study the Effects of Oxycyte® on Ex Vivo Platelet Function.
Wounds, Traumatic Brain Injury, Dermatology
BioSpecifics Technologies Corp. (BSTC):
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Injectable collagenase is marketed as XIAFLEX® in the United States for the treatment of adult Dupuytren’s contracture patients with a palpable cord in the palm by BioSpecifics’ strategic partner Auxilium Pharmaceuticals, Inc. and is approved for Dupuytren’s contracture in the European Union and Canada.
InVisage has built the world’s most sensitive mobile camera: every photon incident is immediately absorbed, and its electronic signal is routed to the right pixel. This translates into clear images in any lighting condition, and sharpness of detail and color.
Trovagene, Inc. is a publicly traded molecular diagnostics company with headquarters in San Diego, California. It has fundamental intellectual property around the remarkable discovery that cell-free DNA, RNA and other types of nucleic acids pass through the kidney into the urine. These “Transrenal Nucleic Acids”, or “TrNAs”, can be diagnostic of diseases such as cancer and infection.
Nexeon has patented a unique way of structuring silicon so that it delivers extended cycle life and significantly increases battery capacity.
In contrast to carbon, Nexeon’s silicon anode materials have a much higher capacity for lithium and as a result are capable of almost ten times the energy capacity per gram (mAh/g).
Oncolytics Biotech Inc. (ONCY): Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers.
Population Diagnostics discovers causative genetic biomarkers to:
Population Diagnostics has intellectual property portfolios in Parkinson’s disease and Autism Spectrum Disorder comprising causative biomarker collections for both therapeutic and diagnostics applications. In addition to active discovery programs in a variety of diseases (see figure), our technology highly enables the cytogenetics diagnostic market. Population Diagnostics pursues alliances with microarray providers serving the cytogenetics community.
CytoSure Haematological Cancer +SNP Array
Reliable detection of copy number changes and loss of heterozygosity on a single array for the haematological malignancies Chronic Lymphocytic Leukaemian CLL, Multiple Myeloma MM, Myeloproliferative Neoplasms MPN and Myelodysplastic Syndromes MDS.
An anti-reflective coating (ARC) is a thin film of material that is processed on to a substrate in order to significantly reduce its visible light reflection. Typical glass and polymer substrates reflect a fair proportion of the light falling directly on them (approximately 4.5-6% per side), with the reflectance increasing as the viewing angle increases. This occurs at both surfaces so in total at least 9-10% of sunlight is reflected from the substrate.
The highly reactive nature of Onto™ means that it is compatible with a diverse range of materials, so it can be used to modify almost any type of surface, including:
uBiome is the world’s first effort to map the human microbiome with citizen science.
While the sequencing of the human genome has provided invaluable knowledge, it is very difficult to change our own genetic makeup. The microbiome, in contrast, is much more easily changed through simple means such as healthful probiotic cultures and other lifestyle interventions.
OrganOx Ltd: OrganOx® Limited is a late-stage medical device development company that was founded in April 2008 as a spin-out from the University of Oxford.
The OrganOx metra™, will be commercially available in 2013 and will enable the repair, preservation and objective viability assessment of livers prior to transplantation for up to 24 hours using normothermic oxygenated blood. Through the use of the metra we aim to increase the number of livers available for transplant.
The metra utilises a patented process of “auto-regulation” allowing the liver to self-regulate pressures and flows of oxygenated blood at normothermic temperatures. The auto-regulation method and algorithms have been developed through over 15 years of research with over 200 pre-clinical perfusions reported in over 30 peer-reviewed publications and reviews.
Organovo Holdings, Inc. (ONVO.PK) has seen tremendous growth in the early trading days of the year. After hitting an intra-week high of $3.99 ONVO reversed slightly and now appears to have settled around 3.20, up nearly 36 percent from the start of the New Year.
The San Diego based company designs and develops functional human tissues using their own proprietary three-dimensional bio-printing technology. ONVO is the developer of the NovoGen MMX Bioprinter™, the world’s only commercial Bioprinter proven to create tissue. Their proprietary technology employs a specified automated platform that works across all tissue and cell types. They are the first company in the world to possess such technology and in recognition; Organovo’s bio-printer was named one of the “Best Inventions of 2010” by TIME Magazine.
OXP Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx and OTC branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API. http://www.oxfordpharmascience.com/
Oxford Pharmascience (LON:OXP) has successfully completed the formulation development for its Safestat formulations of Atorvastatin and Simvastatin, the leading generic statin drugs.
Our pioneering biomarker technology predicts which cancer patients will respond favourably to existing and emerging cancer drugs, allowing treatment to be tailored to individual patients.
We are looking to partner with leading care organisations and drug development companies.
COST EFFECTIVELY MAPPING THE UNDERWORLD
The OXEMS Solution has three fully integrated elements: OXEMS Tags + OXEMS Detector + OXEMS Database. These three combine to deliver the most economical, accurate and intelligent underground asset registration, mapping and management system available – the OXEMS Fully Integrated Solution.
An overview of the OXEMS system for precise surface identification and location of underground assets.
Watch Introduction Animation
Addressing Dopamine Deficiency in Parkinson’s Disease
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company’s technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
Electrochemical Impedance Spectroscopy EIS has the ability to elucidate range of physical and electronic properties of electrochemical systems such as diffusion coefficients, electron transfer rate constants, adsorption mechanisms, charge transfer resistances, capacitances and pore sizes. Find a short introduction to the fundamental principles of EIS and many exciting and pertinent analytical applications regarding the numerous methods in biosensing, the application of EIS with graphene based materials and the use of EIS with screen printed electrodes –Banks et al, Click here:
Applications of High Content Analysis in Pharmaceutical and Consumer Products Safety Testing
Please note, this offer price only applies to individual customers when ordering direct from Oxford University Press, while stock lasts. No further discounts will apply. If you are a bookseller, please contact your OUP sales representative.
Price: £135.00 Sale Price: £67.50